# Humacyte (HUMA) — Analyst Forecast

HUMA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/huma/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 4 | 2 | 0 | 6 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $0.50 | $1.17 | $2.00 | 3 |

Last price $0.44 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 7, 2026 | Barclays | Initiated Coverage | Equal-Weight | $0.50 |
| Aug 13, 2026 | Benchmark | Maintained | Speculative Buy | $1.00 |
| Jul 28, 2026 | BTIG | Maintained | Buy | $2.00 |
| Jun 17, 2026 | TD Cowen | Maintained | Buy | $1.25 |
| Jun 16, 2026 | BTIG | Maintained | Buy | $2.00 |
| Jun 11, 2026 | HC Wainwright & Co. | Maintained | Buy | $4.00 |
| Jun 8, 2026 | BTIG | Maintained | Buy | $2.00 |
| Jun 1, 2026 | Benchmark | Maintained | Speculative Buy | $2.00 |
| May 26, 2026 | HC Wainwright & Co. | Maintained | Buy | $3.00 |
| May 14, 2026 | TD Cowen | Maintained | Buy | $1.50 |
| May 13, 2026 | BTIG | Maintained | Buy | $2.00 |
| Apr 28, 2026 | BTIG | Maintained | Buy | $3.00 |
| Apr 28, 2026 | D. Boral Capital | Maintained | Buy | $25.00 |
| Apr 24, 2026 | D. Boral Capital | Maintained | Buy | $25.00 |
| Apr 21, 2026 | D. Boral Capital | Maintained | Buy | $25.00 |
| Apr 8, 2026 | Barclays | Maintained | Overweight | $1.50 |
| Mar 31, 2026 | Benchmark | Downgraded | Buy → Speculative Buy | $1.00 |
| Mar 30, 2026 | TD Cowen | Maintained | Buy | $1.00 |
| Mar 30, 2026 | Piper Sandler | Maintained | Neutral | $1.00 |
| Mar 27, 2026 | BTIG | Maintained | Buy | $3.00 |

## Frequently Asked Questions

### What is the price target for HUMA stock?

The average 12-month analyst price target for Humacyte (HUMA) is $1.17, with a high estimate of $2.00 and a low of $0.50, across 3 analysts.

### Is HUMA a buy, sell, or hold?

Analysts covering Humacyte currently average a Buy rating: 4 buy, 2 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for HUMA?

The average price target of $1.17 implies 165.45% upside from the last price of $0.44.

### What is the latest analyst rating on HUMA?

On Oct 7, 2026, Barclays initiated coverage of Humacyte at Equal-Weight with a price target of $0.50.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).